Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3375244

Cl.[Ac]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137822-A1 MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY ABDERA THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-20260055180-A1 KIDNEY TARGETING ANTIBODIES ABDERA THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-20250340701-A1 DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN UNIV JOHNS HOPKINS (US) 2025-11-06 US disclosed
US-20250270090-A1 LOW TEMPERATURE SYNTHESIS OF MONAZITE-TYPE MATERIALS UNIVERSITY OF SOUTH CAROLINA 2025-08-28 US disclosed
WO-2025151464-A1 ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-17 WO disclosed
EP-4577576-A1 KIDNEY TARGETING ANTIBODIES Abdera Therapeutics Inc. (US) 2025-07-02 EP disclosed
EP-4577578-A1 DLL3 BINDING MOLECULES AND USES THEREOF Abdera Therapeutics Inc. (US) 2025-07-02 EP disclosed
EP-4577250-A1 MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY Abdera Therapeutics Inc. (US) 2025-07-02 EP disclosed
EP-4577526-A1 VHH ANTIBODY CONJUGATES Abdera Therapeutics Inc. (US) 2025-07-02 EP disclosed
US-12344675-B2 Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex Abdera Therapeutics Inc. (US) 2025-07-01 US disclosed
EP-1091757-A2 ALPHA EMITTING CONSTRUCTS AND USES THEREOF Sloan-Kettering Institute For Cancer Research (US) 2001-04-18 EP disclosed
EP-1073609-A2 BISMUTH-213 GENERATOR AND USES THEREOF Sloan-Kettering Institute For Cancer Research (US) 2001-02-07 EP disclosed
WO-1999061097-A9 ALPHA EMITTING CONSTRUCTS AND USES THEREOF SLOAN KETTERING INST CANCER (US) 2000-06-02 WO disclosed
WO-1999061097-A2 ALPHA EMITTING CONSTRUCTS AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1999-12-02 WO disclosed
WO-1999049931-A2 BISMUTH-213 GENERATOR AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1999-10-07 WO disclosed
US-4446061-A FIREPROOFING, SMOKELESS, PHOSPHITE/PHOSPHONATE MONSANTO COMPANY (US) 1984-05-01 US disclosed
US-4313761-A FIREPROOFING AND SMOKE SUPPRESSANTS MONSANTO COMPANY (US) 1982-02-02 US disclosed
US-4260542-A FLAME RETARDANTS, SMOKE SUPPRESSANTS MONSANTO COMPANY (US) 1981-04-07 US disclosed
US-4206133-A FLAME RETARDANTS AND SMOKE SUPPRESSANTS MONSANTO COMPANY (US) 1980-06-03 US disclosed
US-4133823-A FIREPROOFING, SMOKELESS MONSANTO COMPANY (US) 1979-01-09 US disclosed